Patents by Inventor Timothy C. Scott

Timothy C. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11957893
    Abstract: A neuromodulation therapy is delivered via at least one electrode implanted subcutaneously and superficially to a fascia layer superficial to a nerve of a patient. In one example, an implantable medical device is deployed along a superficial surface of a deep fascia tissue layer superficial to a nerve of a patient. Electrical stimulation energy is delivered to the nerve through the deep fascia tissue layer via implantable medical device electrodes.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 16, 2024
    Assignee: Medtronic, Inc.
    Inventors: Brad C. Tischendorf, John E. Kast, Thomas P. Miltich, Gordon O. Munns, Randy S. Roles, Craig L. Schmidt, Joseph J. Viavattine, Christian S. Nielsen, Prabhakar A. Tamirisa, Anthony M. Chasensky, Markus W. Reiterer, Chris J. Paidosh, Reginald D. Robinson, Bernard Q. Li, Erik R. Scott, Phillip C. Falkner, Xuan K. Wei, Eric H. Bonde, David A. Dinsmoor, Duane L. Bourget, Forrest C M Pape, Gabriela C. Molnar, Joel A. Anderson, Michael J. Ebert, Richard T. Stone, Shawn C. Kelley, Stephen J. Roddy, Timothy J. Denison, Todd V. Smith
  • Patent number: 11957894
    Abstract: A neuromodulation therapy is delivered via at least one electrode implanted subcutaneously and superficially to a fascia layer superficial to a nerve of a patient. In one example, an implantable medical device is deployed along a superficial surface of a deep fascia tissue layer superficial to a nerve of a patient. Electrical stimulation energy is delivered to the nerve through the deep fascia tissue layer via implantable medical device electrodes.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 16, 2024
    Assignee: Medtronic, Inc.
    Inventors: Anthony M. Chasensky, Bernard Q. Li, Brad C. Tischendorf, Chris J. Paidosh, Christian S. Nielsen, Craig L. Schmidt, David A. Dinsmoor, Duane L. Bourget, Eric H. Bonde, Erik R. Scott, Forrest C M Pape, Gabriela C. Molnar, Gordon O. Munns, Joel A. Anderson, John E. Kast, Joseph J. Viavattine, Markus W. Reiterer, Michael J. Ebert, Phillip C. Falkner, Prabhakar A. Tamirisa, Randy S. Roles, Reginald D. Robinson, Richard T. Stone, Shawn C. Kelley, Stephen J. Roddy, Thomas P. Miltich, Timothy J. Denison, Todd V. Smith, Xuan K. Wei
  • Patent number: 11945721
    Abstract: A hydrogen feed stream comprising oxygen and one or more impurities selected from the group consisting of nitrogen, argon, methane, carbon monoxide, carbon dioxide, and water, is purified using a cryogenic temperature swing adsorption (CTSA) process with high overall recovery of hydrogen. The CTSA is regenerated using an inert gas to prevent an explosive mixture of hydrogen and oxygen from occurring.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: April 2, 2024
    Assignee: Air Products and Chemicals, Inc.
    Inventors: Shubhra Jyoti Bhadra, Jeffrey R. Hufton, Timothy C. Golden, Aaron Raymond Scott, Quan Min Shao, Vishrut Garg
  • Publication number: 20240075352
    Abstract: A golf club head with a sole having a low stiffness compliance zone, which allows the face to deflect downward upon impact with a golf ball, is disclosed herein. The compliance zone comprises a plurality of through openings that are filled with one or more filler pieces comprising a low modulus material, all of which are located within three inches of a face section measured along a front-to-back axis of the golf club head.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 7, 2024
    Applicant: Topgolf Callaway Brands Corp.
    Inventors: Irina Ivanova, Brandon D. DeMille, Alan Hocknell, William C. Watson, Timothy G. Scott, Romulus M. Tomimbang, Justin Del Rosario
  • Patent number: 11912545
    Abstract: A wireless hoist system including a first hoist device having a first motor and a first wireless transceiver and a second hoist device having a second motor and a second wireless transceiver. The wireless hoist system includes a controller in wireless communication with the first wireless transceiver and the second wireless. The controller is configured to receive a user input and determine a first operation parameter and a second operation parameter based on the user input. The controller is also configured to provide, wirelessly, a first control signal indicative of the first operation parameter to the first hoist device and provide, wirelessly, a second control signal indicative of the second operation parameter to the second hoist device. The first hoist device operates based on the first control signal and the second hoist device operates based on the second control signal.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: February 27, 2024
    Assignee: Milwaukee Electric Tool Corporation
    Inventors: Matthew Post, Gareth Mueckl, Matthew N. Thurin, Joshua D. Widder, Timothy J. Bartlett, Patrick D. Gallagher, Jarrod P. Kotes, Karly M. Schober, Kenneth W. Wolf, Terry L. Timmons, Mallory L. Marksteiner, Jonathan L. Lambert, Ryan A. Spiering, Jeremy R. Ebner, Benjamin A. Smith, James Wekwert, Brandon L. Yahr, Troy C. Thorson, Connor P. Sprague, John E. Koller, Evan M. Glanzer, John S. Scott, William F. Chapman, III, Timothy R. Obermann
  • Publication number: 20210299055
    Abstract: The present invention contemplates a method of treating a solid cancerous tumor in a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of a halogenated xanthene (HX), the lactone thereof, a pharmaceutically acceptable salt, or a C1-C4 alkyl or aromatic ester thereof (collectively an HX compound) to that mammalian subject, and liquid and solid pharmaceutical compositions for administering the HX compound. In addition, a method of inhibiting the growth of a GI tract carcinoma of a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of an HX compound, as well as solid and liquid pharmaceutical compositions therefor.
    Type: Application
    Filed: March 26, 2021
    Publication date: September 30, 2021
    Applicants: Provectus Pharmatech, Inc., Governors of the University of Calgary
    Inventors: Eric A. WACHTER, Dominic RODRIGUES, Edward V. PERSHING, Bruce HOROWITZ, Timothy C. SCOTT, H. Craig DEES, Aru NARENDRAN
  • Patent number: 8974363
    Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: March 10, 2015
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, John Smolik, Eric A. Wachter, Walter G. Fisher
  • Patent number: 8557298
    Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: October 15, 2013
    Assignee: Provectus Pharmatech, Inc.
    Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
  • Patent number: 8470296
    Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: June 25, 2013
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Publication number: 20110097280
    Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
    Type: Application
    Filed: December 30, 2010
    Publication date: April 28, 2011
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Patent number: 7863047
    Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: January 4, 2011
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Publication number: 20100076246
    Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.
    Type: Application
    Filed: August 19, 2009
    Publication date: March 25, 2010
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Patent number: 7648695
    Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: January 19, 2010
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott
  • Publication number: 20090117199
    Abstract: A method for the treatment of cancer, particularly a metastatic melanoma or a neoplastic lesion, the method comprising intralesional administration of a hydrophilic vehicle comprising 4,5,6,7-Tetrachloro-2?,4?,5?,7?-tetraiodofluorescein, or a physiologically acceptable salt thereof, at a concentration of about 0.1 w/v % up to about 20 w/v % and an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chlorine, a phosphate and a nitrate, wherein the electrolyte is at a concentration of between about 0.1 w/v % and about 2 w/v % and the pH of the solution between about 4 to about 10.
    Type: Application
    Filed: December 5, 2008
    Publication date: May 7, 2009
    Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
  • Publication number: 20080311035
    Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.
    Type: Application
    Filed: August 19, 2008
    Publication date: December 18, 2008
    Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
  • Patent number: 7427389
    Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.
    Type: Grant
    Filed: February 3, 2005
    Date of Patent: September 23, 2008
    Assignee: Provectus Pharmatech, Inc.
    Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
  • Publication number: 20080207746
    Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
    Type: Application
    Filed: April 25, 2008
    Publication date: August 28, 2008
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Patent number: 7402299
    Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
    Type: Grant
    Filed: November 30, 2004
    Date of Patent: July 22, 2008
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Patent number: 7390668
    Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: June 24, 2008
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Publication number: 20080118578
    Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.
    Type: Application
    Filed: November 8, 2007
    Publication date: May 22, 2008
    Inventors: H. Craig Dees, Timothy C. Scott, John Smolik, Eric A. Wachter, Walter G. Fisher